Pharmacovigilance – News and Features

The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of an investigational cancer compound.

University of California researchers demonstrate how they have created nanotubes that can hold therapeutic drugs and deliver in a highly-controlled manner.

Lectus receives the award based on the significant achievements and progress made by the company.

Sage-N will develop and sell products based on the proteomic search software, which was licensed to Thermo Fisher by the University of Washington.

The newly-established laboratory is now fully operational and can provide mass spectrometry-based technologies including metabolomics and proteomics.

Experts from Stellenbosch University have highlighted the role that genetics may play in treating the current global tuberculosis pandemic.

The Company to start Phase 1 human safety study of its investigational eiRNA therapy for the treatment of chronic hepatitis B infection.

The SBIR $233,598 Phase I grant will be used to develop high throughput technology targeting Tau OLIGOMERS.

Lumera extends the collaboration agreement and gain rights to commercialize the jointly developed intellectual property.

ChanTest's primary focus is on ion channels that may be either deliberate therapeutic targets for new drug development, or unintended targets that can result in unwanted side-effects from new drugs.